The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters
about
The Classification of Substance Use Disorders: Historical, Contextual, and Conceptual ConsiderationsA pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disordersAdvancing performance measures for use of medications in substance abuse treatmentSelection of medicines in Chilean public hospitals: an exploratory study.The Reinforcing Therapist Performance (RTP) experiment: study protocol for a cluster randomized trial.The adoption of alcohol pharmacotherapies in the Clinical Trials Network: the influence of research network participation.Impact of research network participation on the adoption of buprenorphine for substance abuse treatment.Development of a Multilevel Framework to Increase Use of Targeted Evidence-Based Practices in Addiction Treatment Clinics.From research to the real world: buprenorphine in the decade of the Clinical Trials NetworkUnderstanding attitudes towards use of medication in substance abuse treatment: A multilevel approach.Racial and Ethnic Composition as a Correlate of Medication Availability within Addiction Treatment Organizations.Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sectorFactors affecting willingness to provide buprenorphine treatment.What Influences Participation in QI? A Randomized Trial of Addiction Treatment Organizations.The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment.Structural and cultural barriers to the adoption of smoking cessation services in addiction treatment organizations.Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizationsTotal quality management and performance in substance abuse treatment centers.Smoking Cessation Services in Adolescent Substance Abuse Treatment: Opportunities Missed?Examining the sustainment of the Adolescent-Community Reinforcement Approach in community addiction treatment settings: protocol for a longitudinal mixed method study.Adoption and implementation of medications in addiction treatment programs.Counselor attitudes toward the use of naltrexone in substance abuse treatment: a multi-level modeling approachUsing medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation.Effect of an organizational linkage intervention on staff perceptions of medication-assisted treatment and referral intentions in community correctionsBarriers to the implementation of medication-assisted treatment for substance use disorders: the importance of funding policies and medical infrastructure.A longitudinal examination of alcohol pharmacotherapy adoption in substance use disorder treatment programs: patterns of sustainability and discontinuationBarriers to use of pharmacotherapy for addiction disorders and how to overcome them.How do providers serving American Indians and Alaska Natives with substance abuse problems define evidence-based treatment?Management systems, patient quality improvement, resource availability, and substance abuse treatment qualityTreatment strategy profiles in substance use disorder treatment programs: A latent class analysisPhysicians in the substance abuse treatment workforce: understanding their employment within publicly funded treatment organizations.Provision of onsite HIV Services in Substance Use Disorder Treatment Programs: A Longitudinal Analysis.Perceptions of the state policy environment and adoption of medications in the treatment of substance use disorders.A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatmentTreating Opioid Dependence with Buprenorphine in the Safety Net: Critical Learning from Clinical Data.Financial factors and the implementation of medications for treating opioid use disorders.A Rasch model analysis of evidence-based treatment practices used in the criminal justice systemDisparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States.Low Rates of Adoption and Implementation of Rapid HIV Testing in Substance Use Disorder Treatment Programs.Rural substance use treatment centers in the United States: an assessment of treatment quality by location
P2860
Q26739919-1D0428D1-41B1-4995-977D-8460F32BCAF0Q27000732-D645C079-D778-47B5-B76A-4DAF9436299BQ28744415-1C0303B2-4BAF-4C0A-8D99-430FE5703C15Q30532048-32C48D79-3130-400D-B7E6-61A94C9DE0F7Q33669510-90EB19A2-59F4-4BC1-967E-AD3A8FAB0B45Q33716545-D00D7572-0214-4CB6-AB4B-888271F3C9E3Q33776944-C80940E3-A6F2-4F25-B0A4-0C0EF3FD11C2Q33777086-A5BB882B-9623-4DCC-AE88-F30ADA75A20EQ33783274-ACBA5FDE-3802-4B84-A0E8-8D07BD0A0AC1Q33791771-54A36A5D-5225-4474-A959-EBFA8F436E19Q33803543-16A8F505-3D73-48CF-959B-D09F8AD3E24AQ33810987-71C50CEB-561A-4DC1-A525-FA6689EBD225Q33836333-B63BCBD1-D35F-4903-899D-6DB3D2D6161BQ34037035-630D54F1-C08A-4434-AA7A-FC04225B6A28Q34050760-C23EDFB7-5369-4BAB-ABF3-F34F801D1802Q34070104-F8486AA4-87AE-41D5-ADE7-B49AD154CD4EQ34111054-EA807F60-4067-4625-9D3C-206E26011CB0Q34292827-AE56F957-479A-4D6D-A62E-1296CD00466DQ34528070-E667D29C-54D1-4DB3-B561-FA81D6737284Q34570585-62E019C0-B05E-4A4D-B075-8BB59A81CF36Q34607338-0F5E67F6-7993-4180-84DA-F99E44806A02Q34762315-930A3E45-D3D1-4EFC-A2E3-0F44727A1378Q34925449-DC34E692-43A5-49F2-9B73-7A5E32DC8722Q35007640-85E56D72-9925-4EBB-AB5B-1779FA235E72Q35042742-4DD4D3D0-0972-471C-AD81-40AE02E50056Q35075932-4508A22B-DA4A-417A-8FD6-8F3DFD61ABE9Q35490468-CAD1C5B6-B128-4088-8BDA-5CE95FF8A856Q35602408-F6069ECC-B6AB-4B49-9D47-9CE64AA22CBBQ35791326-FB2708CB-26C4-497C-AE3C-AB2CEA1195A2Q35875486-24E92423-6F69-4580-88B4-9F092D92D591Q35937004-5DBF9C30-4443-46A1-9482-7086DE892094Q36030916-9861364B-5613-41A3-9E7C-8B163241433AQ36192673-D0796DA3-5780-47AC-956F-E64EF24534EEQ36364490-09F48B18-8DB7-4B6F-BEF1-28080FCB413DQ36367544-B35A061E-D5DA-4168-B56F-653608A6C424Q36381418-118F5A90-B945-4530-9D91-833E8BF3286BQ36541145-46F68B68-63B6-4650-8A1B-8779C10DE21CQ36597560-1E64C25C-1425-4984-A198-6E5A7B3FC90EQ36642977-7AFBF043-2C0C-412D-ABB8-9EF088E38D7DQ36643013-551A6CAE-AF2D-4179-8B4B-68722BBE0E11
P2860
The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The adoption of medications in ...... istics and technology clusters
@ast
The adoption of medications in ...... istics and technology clusters
@en
type
label
The adoption of medications in ...... istics and technology clusters
@ast
The adoption of medications in ...... istics and technology clusters
@en
prefLabel
The adoption of medications in ...... istics and technology clusters
@ast
The adoption of medications in ...... istics and technology clusters
@en
P2093
P2860
P1476
The adoption of medications in ...... istics and technology clusters
@en
P2093
Hannah K Knudsen
Lori J Ducharme
Paul M Roman
P2860
P304
P356
10.1016/J.DRUGALCDEP.2006.08.013
P577
2006-09-12T00:00:00Z